AKTS
Aktis Oncology, Inc.
Aktis Oncology, Inc. (AKTS) has 4 SEC Form 4 filings (14 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Jul 22, 2026.
Insiders have net sold $3.0M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Matthew Roden
- Employees:79
- HQ:Boston, MA, US
- IPO:2026-01-09
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.0M
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Market Cap
$1.3B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Director | Sale | 4,856 | $119K | Jul 22 | SEC ↗ | |
Herrmann KenFirst filing | Director | Sale | 3,065 | $77K | Jul 20 | SEC ↗ |
Ron-Bigger ShulamitFirst filing | Chief Operating Officer | Sale | 50,000 | $1.4M | Jul 10 | SEC ↗ |
Czibere AkosFirst filing | Chief Medical Officer | Sale | 50,000 | $1.4M | Jul 10 | SEC ↗ |
Related companies
Aktis Oncology, Inc. is in the Healthcare sector.